Advanced

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.

Nishimura, Toshide LU ; Kawamura, Takeshi; Sugihara, Yutaka LU ; Bando, Yasuhiko; Sakamoto, Shigeru; Nomura, Masaharu; Ikeda, Norihiko; Ohira, Tatsuo; Fujimoto, Junichiro and Tojo, Hiromasa, et al. (2014) In Clinical and Translational Medicine 3(1).
Abstract
The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and... (More)
The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical and Translational Medicine
volume
3
issue
1
publisher
Springer
external identifiers
  • pmid:25635206
ISSN
2001-1326
DOI
10.1186/s40169-014-0038-x
language
English
LU publication?
yes
id
068a88c4-4662-4b39-94c8-889eccc5a23c (old id 5038965)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25635206?dopt=Abstract
date added to LUP
2015-02-05 18:25:44
date last changed
2016-09-20 04:07:32
@article{068a88c4-4662-4b39-94c8-889eccc5a23c,
  abstract     = {The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.},
  articleno    = {61},
  author       = {Nishimura, Toshide and Kawamura, Takeshi and Sugihara, Yutaka and Bando, Yasuhiko and Sakamoto, Shigeru and Nomura, Masaharu and Ikeda, Norihiko and Ohira, Tatsuo and Fujimoto, Junichiro and Tojo, Hiromasa and Hamakubo, Takao and Kodama, Tatsuhiko and Andersson, Roland and Fehniger, Thomas E and Kato, Harubumi and Marko-Varga, György},
  issn         = {2001-1326},
  language     = {eng},
  number       = {1},
  publisher    = {Springer},
  series       = {Clinical and Translational Medicine},
  title        = {Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.},
  url          = {http://dx.doi.org/10.1186/s40169-014-0038-x},
  volume       = {3},
  year         = {2014},
}